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Within the mass spectrometric study of bisubstituted isoquinolines that possess great potential
as prolylhydroxylase inhibitor drug candidates (e.g., FG-2216), unusually favored gas-phase
formations of carboxylic acids after collisional activation were observed. The protonated
molecule of [(1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid was dissociated,
yielding the 1-chloro-4-hydroxy-isoquinoline-3-carboxylic acid methyleneamide cation. Sub-
sequent dissociation caused the nominal elimination of 11 u that resulted from the loss of HCN
and concomitant addition of oxygen to the product ion, which formed the protonated
1-chloro-4-hydroxy-isoquinoline-3-carboxylic acid. The preference of this structure under mass
spectrometric conditions was substantiated by tandem mass spectrometry analyses using the
corresponding methyl ester (1-chloro-4-hydroxy-isoquinoline-3-carboxylic acid methyl ester)
that eliminated methylene (14 u) upon collisional activation. Moreover, the major product
ion of 1-chloro-4-hydroxy-isoquinoline-3-carboxylic acid, which resulted from the loss of water
in MS3 experiments, restored the precursor ion structure by re-addition of H2O. Evidences for
these phenomena were obtained by chemical synthesis of proposed gas-phase intermediates,
H/D exchange experiments, high-resolution/high accuracy mass spectrometry at MSn level,
and “ping-pong” analyses (MS7, in which the precursor ion was dissociated and the respective
product ion isolated to regenerate the precursor ion for repeated dissociation. Based on these
results, dissociation pathways for [(1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic
acid were suggested that can be further utilized for the characterization of structurally related
compounds or metabolic products in clinical, forensic, or doping control analysis. (J Am Soc
Mass Spectrom 2008, 19, 151–158) © 2008 American Society for Mass SpectrometryProlyl hydroxylases have been subject of variousstudies because of their importance in severalbiochemical pathways and, thus, related diseases
in case of impaired activity. Proline hydroxylation was
identified as a key factor in the biosynthesis and matu-
ration of collagen [1, 2], which requires 4-hydroxylation
of specific proline residues (in X-Pro-Gly motifs) to
establish the characteristic triple-helical structure. How-
ever, during life-threatening fibrotic states, inappropri-
ately large amounts of collagen are produced, and the
inhibition of proline hydroxylation is desired to divert
the collagen biosynthesis into a degradative pathway
[3]. More recently, the catalytic role of prolyl hydroxy-
lase isoforms in modifying conserved prolines of two
oxygen-dependent degradation domains in the hypox-
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doi:10.1016/j.jasms.2007.11.003ia-inducible factor (HIF)-1 was identified [4–6]. The
members of the 2-oxoglutarate-dependent dioxygenase
superfamily enable the hydroxylation of the proline
residues 402 and 564 of HIF-1 and promote its degra-
dation via ubiquitylation and subsequent proteasomal
destruction [7–9]. As a consequence, the presence of
HIF-1 in organisms is regulated in an oxygen-depen-
dent manner, which represents the basis of cellular
oxygen sensing [10–12] and, thus, the activity of hy-
poxic response genes that control angiogenic [13, 14]
and erythropoietic processes [15–17].
Based on these findings and the involved molecular
principles, numerous compounds were designed and
tested regarding their properties to inhibit prolyl hydrox-
ylase activities to counteract and correct symptoms of
serious diseases. Derivatives of 2-oxoglutarate [18, 19],
hydroxyanthraquinones [20], 5-acyl sulfonamides [21],
dihydroxybenzoates [22], hydroxyquinolines [23], pyrazo-
lopyridines [24], andmany other compounds [25–28]were
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152 THEVIS ET AL. J Am Soc Mass Spectrom 2008, 19, 151–158prepared and studied. One of the most promising class of
candidates, which currently undergoes Phase II clinical
trials [29], comprises an isoquinoline core with a 3-posi-
tioned carboxyl residue that was converted into its amide
using glycine (Scheme 1-1). Various studies proved the
efficiency of the lead drug candidate FG-2216, an orally
active compound, in stimulating erythropoiesis for the
treatment of anemia [30, 31]. In the course of analytical
assay development concerning model prolyl hydroxylase
inhibitors (PHIs), the isoquinoline-derived PHI [(1-chloro-
4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid was
synthesized, and subsequently studied using electrospray
ionization and high-resolution/high accuracy ion trap/
orbitrapmass spectrometry. Diagnostic product ions char-
acterizing the target analyte and related compounds were
elucidated in MSn experiments with in-time and in-space
dissociation as well as comparison of ions formed under
gas-phase conditions with chemically synthesized refer-
ence substances. The obtained results provided evidence
for gas-phase reactions that include the addition of oxygen
as well as water generating a favored ion with isoquino-
line-3-carboxylic acid structure. The resulting data on the
dissociation behavior of structural analogs shall support
the identification of such compounds and/or metabolites
in clinical, forensic, and doping control analysis.
Experimental
To allow method developments aiming at clinical, fo-
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Scheme 1. Chemical structures of investigated: 1, general struc-
ture of isoquinoline-3-carboxylamide-based prolylhydroxylase in-
hibitors, 2, drug candidate (mol wtmonoisotopic  280), 3, 1-chloro-
4-hydroxy-isoquinoline-3-carboxylic acid (mol wtmonoisotopic 
223), 4, 1-chloro-4-hydroxy-isoquinoline-3-carboxylic acid methyl
ester (mol wtmonoisotopic  237), and 5, drug candidate 2 after
H/D-exchange in D2O/MeOD (mol wtmonoisotopic  283). R1-R5
represent various substituents, e.g., hydrogens, halogens, hy-
droxyl functions, alkyl, or alkyloxy residues, etc.rensic, or preventive doping research, therapeutics inclinical studies or structural analogs that resemble
physicochemical properties of future drug candidates
are studied using informative and sensitive analytical
tools such as mass spectrometry, which are applicable
also to biological matrices.
Chemicals and Reagents
Phthalic anhydride (99%), methyl isocyanoacetate
(97%), phosphorus oxychloride (99%), glycine methyl
ester hydrochloride (99%), (benzotriazol-1-yloxy)tripyr-
rolidinophosphonium hexafluorophosphate (PyBOP,
98%), triethylamine (99%), N-ethyldiisopropylamine
(98%), deuterium oxide (D2O, 99.9%), and water-
18O
(10%) were purchased from Sigma (Deisendorf, Ger-
many). Silica gel 60 (70-230 mesh) and solvents (meth-
anol, tetrahydrofurane, dichloromethane, and dimeth-
ylformamide, all analytical grade) were obtained from
Merck (Darmstadt, Germany). Deionized water used
for sample preparation and buffer solutions was of
MilliQ grade.
Synthesis and Characterization of Model
Compound
One model PHI, [(1-chloro-4-hydroxy-isoquinoline-3-car-
bonyl)-amino]-acetic acid (Scheme 1-2) and related deriv-
atives were synthesized as described elsewhere [32, 33].
Briefly, phthalic anhydride and methyl isocyanatoacetate
were mixed to yield to 5-(2-carboxyphenyl)-4-methoxy-
carbonyl-1,3-oxazole, which was further condensed to
methyl 4-hydroxy-1-oxo-1,2-dihydroisoquinoline-3-car-
boxylate, which is referred to as Compound 4 (Scheme 1)
that allowed the preparation of Compound 3 (Scheme 1)
after alkaline hydrolysis. Subsequent chlorination at C-1,
amide formation at the 3-carboxyl function using glycine
methyl ester, and alkaline hydrolysis gave rise to Com-
pound 2. After purification using flash chromatography
(dichloromethane and silica gel), the pure reference com-
pound was characterized by nuclear magnetic resonance
spectroscopy (NMR) with 1H, H,H-COSY, H,C HMQC,
H,C HMBC, and DEPT experiments employing a Bruker
DRX 500 MHz instrument (Bruker, Karlsruhe, Germany)
equipped with a 5 mm inverse probe head (z-gradient
coil). Approximately 10 mg of 2 was dissolved in deuter-
ated dimethylsulfoxide, and spectra were recorded at
room temperature. In addition, the elemental composition
of the synthesized substance was determined using high-
resolution/high accuracy mass spectrometry utilizing an
LTQ Orbitrap (Thermo, Bremen, Germany) at a resolving
power of 30,000 (FWHM).
Stock and Working Solutions
The stock solutions of the analytes was prepared in
acetonitrile at 1 mg/mL and stored at 2 to 8 °C. Work-
ing solutions were prepared at 2 g/mL using acetoni-
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formic acid.
Electrospray Ionization-Tandem Mass
Spectrometry
ESI-MS(/MS) was performed on a LTQ Orbitrap
(Thermo, Bremen, Germany) mass spectrometer. The
instrument was operated in positive ionization mode
and calibrated using the manufacturer’s calibration
mixture (containing caffeine, MRFA, and Ultramark
that yield a total of seven reference masses). Mass
accuracies  2 ppm (calculated from 30 averaged spec-
tra) were determined before and after the period of
analysis of target compounds. Working solutions were
introduced into the mass spectrometer using a syringe
pump at a flow rate of 5 L/min. The ionization voltage
was 3.0 kV, the capillary temperature was set to 275 °C,
and protonated precursor ions were isolated using a
width of 1.4 Da. The protonated species were dissoci-
ated at normalized collision energies between 10 and 35
(arbitrary units). Damping gas in the linear ion trap was
helium (purity grade 5.0), and gas supplied to the
curved linear ion trap (CLT) was nitrogen obtained
from a CMC nitrogen generator (CMC Instruments,
Eschborn, Germany).
H/D-Exchange Experiments
To provide more detailed mass spectrometric informa-
tion for product ion characterization and suggestion of
dissociation pathways, hydrogen/deuterium-exchange
was performed by dissolving 1 mg of Compound 2 in 1
mL of deuterated methanol (MeOD) and deuterium
oxide (D2O) (1:1, vol:vol). After incubation at room
temperature for 10 min, the solution was diluted 1:50 in
MeOD/D2O (1:1, vol:vol) and introduced into the LTQ
Orbitrap mass spectrometer via the syringe pump.
Analyses were carried out under identical conditions as
applied for Compound 2 without H/D-exchange.
Liquid Chromatography-Tandem Mass
Spectrometry
Additional mass spectrometric studies were performed
using an Agilent 1100 Series liquid chromatograph
(Waldbronn, Germany) coupled to an Applied Biosys-
tems API 4000 QTrap mass spectrometer (Darmstadt,
Germany) with electrospray ionization to probe for
differences in dissociation pathways using in-space
instead of in-time tandem mass spectrometry and nitro-
gen as collision gas. The LC was equipped with a
Macherey-Nagel Pyramid column (4.0  70 mm, 5 m
particle size), and the eluents used were 5 mM ammo-
nium acetate containing 0.1% acetic acid (mobile phase
A) and acetonitrile/methanol (1:1, vol:vol; mobile phase
B). A gradient was employed starting at 0% B (1 min)
increasing to 100% B within 6.5 min followed by re-equilibration at 0% B for 1.5 min. The flow rate was set
to 800 L/min. Nitrogen was employed as curtain and
collision gas (5  103 Pa) delivered from a CMC
nitrogen generator (CMC Instruments, Eschborn, Ger-
many), and collision offset voltages or nozzle-skimmer
dissociation settings were optimized for each experi-
ment (vide infra).
Results and Discussion
Synthesis and Characterization of the Model PHI
[(1-Chloro-4-Hydroxy-Isoquinoline-3-Carbonyl)-
Amino]-Acetic Acid
The synthesis yielded the intended structure with an
overall yield 8.6%, which provided sufficient amounts
of pure analyte necessary for structure characterization
and mass spectrometric studies. Compound 2 was
characterized by NMR analyses: 1H NMR (500 MHz,
d6-DMSO) : 8.35 (m, 1H, H-5), 7.99 (m, 1H, H-6), 7.99
(m, 1H, H-7), 8.35 (m, 1H, H-8), 4.05 (d, 2H, H-13); 13C
NMR (125 MHz, d6-DMSO) : 139.1 (C-1), 120.9 (C-3),
155.0 (C-4), 123.5 (C-5), 132.2 (C-6), 132.2 (C-7), 126.6
(C-8), 130.0 (C-9), 129.0 (C-10), 169.3 (C-11), 41.35 (C-13),
171.1 (C-14).
Electrospray Ionization-tandem Mass Spectrometry
The CID behavior of the model target analyte 2 was
studied employing high-resolution/high accuracy (tan-
dem) mass spectrometry with a hybrid linear ion trap-
orbitrap instrument. The characterization of dissocia-
tion pathways of new emerging therapeutics is of
particular importance in clinical research as well as
sports drug testing. Metabolite identification and char-
acterization nowadays strongly relies on mass spectro-
metric results, which necessitate a comprehensive set of
information to assign dissociation pathways to analyte
structures in complex biological matrices such as blood
or urine.
PHIs have been the subject of various recent studies
[23, 24], and the product ion spectrum of 2 derived from
the protonated molecule [M  H] at m/z 281 is
depicted in Figure 1a. Upon weak collisional activation
(normalized collision energy 15 arbitrary units, Xcali-
bur Software version 2.0; Thermo, San Jose, CA), the
precursor ion consecutively eliminates water (18 u)
and carbon monoxide (28 u) yielding the product ions
at m/z 263 and 235, respectively. Moreover, a nominal
loss of C2H3NO (57 u) is observed generating the ion
at m/z 224, which subsequently releases water (18 u)
to yield the product ion at m/z 206 (Table 1). By means
of MS3 and MS4 experiments, it was demonstrated that
the ion at m/z 235 gives rise to m/z 224 (Figure 1b). This
corresponded to a nominal loss of 11 u that was
attributed to the elimination of HCN (27 u) concerted
with an addition of oxygen (16 u) according to high-
resolution/high accuracy mass spectrometry results
(Table 1). Due to this unusual behavior, various exper-
154 THEVIS ET AL. J Am Soc Mass Spectrom 2008, 19, 151–158iments, including linear ion trap MSn and in-space
MS/MS, H/D-exchange, as well as synthesis and anal-
ysis of putative compounds generated in situ as gas-
phase ions under CID conditions, were conducted to
elucidate the mechanism underlying the observed dis-
sociation behavior.
The influence of ion trapping on the phenomenon of
the release of HCN and the simultaneous addition of
oxygen to the ion at m/z 235 was evaluated using a
triple-stage quadrupole tandem mass spectrometer
(Applied Biosystems QTrap 4000, see above). Employ-
ing an elevated declustering potential of 100 V that
induces a nozzle-skimmer dissociation of the proton-
ated precursor ion to generate m/z 235, pseudo-MS3
measurements were performed that yielded a highly
comparable dissociation pattern as observed in ion
trap/orbitrap analyses. The major product ions formed
from m/z 235 using in-space CID were found at m/z 224
and m/z 206 (Figure 1c), which allowed the assumption
that the rearrangement causing the loss of HCN and the
addition of oxygen did not necessitate ion trapping
conditions and was not dependent on resonant excita-
tion of ions. Exchanging hydrogen by deuterium atoms
in Compound 2 yielded the precursor ion at m/z 285
(Scheme 1, 5) due to the incorporation of three deuter-
ons plus one replacing the proton, which is added
during the ionization process. The dissociation of the
deuterated precursor ion [MD3  D]
 provided evi-
dence for the loss of D2O (20 u) followed by the
elimination of CO (28) giving rise to product ion at
m/z 237 that comprised two deuterium atoms (Table 1).
Moreover, product ions at m/z 225 and 227 were de-
tected, which proved the existence of two dissociation
pathways and supposedly two different structures of
product ions with identical elemental compositions in
case of the unlabeled Compound 2; i.e., the precursor
ion of the deuterated Compound 5 eliminated isocya-
natomethane containing one deuterium atom
(CH2DNCO, 58 u) to yield m/z 227, while MS
3 exper-
iments using m/z 237 as the second precursor ion
generated the product ion at m/z 225 that resulted from
the loss of DCN accompanied by the uptake of one
oxygen atom (Table 1). The source of the added oxygen,
however, remained unclear. Based on these data, disso-
ciation pathways for the protonated molecule of 2 were
proposed as illustrated in Scheme 2. Two parallel routes
led to the product ion atm/z 224, which is assumed to be
composed by two species. Route 1 is suggested to be
initiated by the losses of water and carbon monoxide (a)
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Figure 1. ESI product ion spectra of (a) Compo
units; (b) Compound 2, LTQ-Orbitrap, MS3 exper
units; (c) Compound 2, API 4000 QTrap, pseudo-
100 V, collision offset voltage  20 V; (d) Co
281–224, collision energy  25 arbitrary units; (
isoquinoline-3-carboxylic acid), collision energy
Orbitrap, (1-chloro-4-hydroxy-isoquinoline-3-ca
arbitrary units.that yielded the 1-chloro-4-hydroxy-isoquinoline-3-car-
boxylic acid methyleneamide cation at m/z 235 (Scheme
2). The elimination of HCN (b) can form a highly
reactive carbene that subsequently adds oxygen (c) to
yield m/z 224. In contrast, route 2 is proposed to consist
of an immediate release of isocyanatomethane (d) from
the protonated molecule. Here, a rearrangement includ-
ing hydrogen transfer from N-2 to the leaving group
and migration of the terminal carboxyl function are
suggested because only one deuterium atom was elim-
inated with the loss of CH2DNCO in H/D-exchange
experiments (vide supra).
Supporting information for the suggested structures of
the product ions atm/z 235 and 224were obtained by further
dissociation as well as analyses of synthesized 1-chloro-4-
hydroxy-isoquinoline-3-carboxylic acid (Scheme 1-3)
and its methyl ester (Scheme 1-4). Besides abundant
signals at m/z 224 and 206, the ion at m/z 235 (derived
from Compound 2) yielded a product ion at m/z 178 in
MS3 experiments (Figure 1b, Table 1). Its generation
was assigned to the loss of N-methylene-formamide
(CH2NCHO, 57 u), which is possible after isomeriza-
tion of m/z 235 with charge delocalization via a facile
1,2-elimination assuming the structure presented in
Scheme 2 (e). The CID of the product ion at m/z 224
mainly yielded an ion resulting from the loss of water
only (m/z 206) but also products resulting from the
consecutive release of CO (m/z 196) and water (m/z 178)
(Figure 1d). The analysis of synthesized 1-chloro-4-
hydroxy-isoquinoline-3-carboxylic acid (Compound 3),
which represents the proposed structure of the product
ion at m/z 224, demonstrated an identical dissociation
behavior as the product ion derived from Compound 2,
which substantiated the postulated gas-phase ion struc-
ture (Figure 1e). Measuring the corresponding methyl
ester of 1-chloro-4-hydroxy-isoquinoline-3-carboxylic
acid (Compound 4) under identical conditions gave rise
to a product ion spectrum depicted in Figure 1f. The
protonated molecule at m/z 238 generated an abundant
signal upon collisional activation at m/z 224, which
represented the free carboxylic acid and, thus, demon-
strated the favored gas-phase ion structure of m/z 224 as
the loss of methylene is rather seldom using ESI and
CID.
Finally, the preferred generation of m/z 224 was
further substantiated by isolation of its major product
ion at m/z 206 (Scheme 2). The isolation and storage of
m/z 206 in the linear ion trap without excitation enabled
the restoration of m/z 224 by the re-addition of water
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™3
2, LTQ-Orbitrap, collision energy  15 arbitrary
t onm/z 281–235, collision energy 17 arbitrary
experiment on m/z 235, declustering potential 
nd 2, LTQ-Orbitrap, MS3 experiment on m/z
mpound 3, LTQ-Orbitrap, (1-chloro-4-hydroxy-
0 arbitrary units; and (f) Compound 4, LTQ-
lic acid methyl ester), collision energy  17™™™
und
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molecule remained unclear, but the use of deuterium
Table 1. Elemental compositions of protonated molecules and r
experiments
Com-
pound
Precursor ion (m/z)
Elemental
comp. (exp.)
Er
(ppMS2 MS3 MS4
2 281.0326 C12H10O4N2Cl 0
263.0219 C12H8O3N2Cl 0
235.0269 C11H8O2N2Cl 0
224.0109 C10H7O3NCl -0
206.0003 C10H5O2NCl -0
3 224.0110 C10H7O3NCl 0
206.0004 C10H5O2NCl 0
4 238.0265 C11H9O3NCl -0
224.0108 C10H7O3NCl -0
5 285.0582 C12H6D4O4N2Cl 2
237.0400 C11H6D2O2N2Cl 2
225.0174 C10H6DO3NCl 1
207.0068 C10H4DO2NCl 0oxide and water-18O as solvents for Compound 2 inoffline-ESI-MS/MS experiments excluded the possibil-
ity that it originated from the solvation/ionization
ing product ions using high resolution/high accuracy MSn
Collision
energy
(arb. units)
Product
ion (m/z)
Elemental
comp. (exp.)
Error
(ppm)
Cleaved
species
15 263.0219 C12H8O3N2Cl 0.3 H2O
235.0269 C11H8O2N2Cl 0.1 H2O, CO
224.0110 C10H7O3NCl 0.4 C2H3NO
206.0004 C10H5O2NCl 0.3 C2H3NO, H2O
10 235.0269 C11H8O2N2Cl 0.1 CO
17 224.0110 C10H7O3NCl 0.4 HCN ,
addition of ½
O2
206.0004 C10H5O2NCl 0.3 HCN , H2O,
addition of ½
O2
196.0160 C9H7O2NCl -0.1 HCN , CO,
addition of ½
O2
178.0054 C9H5ONCl -0.3 HCN , CO,
H2O, addition
of ½ O2
25 206.0003 C10H5O2NCl -0.2 H2O
196.0160 C9H7O2NCl -0.1 CO
178.0054 C9H5ONCl -0.3 H2O, CO
20 224.0110 C10H7O3NCl 0.4 addition of
H2O
196.0160 C9H7O2NCl -0.1 H2O
178.0053 C9H5ONCl -0.5 CO
150.0104 C8H5NCl -0.9 CO (2x)
40 206.0004 C10H5O2NCl 0.5 H2O
196.0160 C9H7O2NCl -0.1 CO
178.0054 C9H5ONCl -0.3 H2O, CO
20 224.0110 C10H7O3NCl 0.4 addition of
H2O
196.0161 C9H7O2NCl 0.6 H2O
178.0055 C9H5ONCl 0.5 CO
150.0105 C8H5NCl -0.1 CO (2x)
16 224.0109 C10H7O3NCl 0.1 CH2
206.0003 C10H5O2NCl 0.0 CH2, H2O
196.0160 C9H7O2NCl -0.1 CH2, CO
178.0053 C9H5ONCl -0.6 CH2, CO, H2O
40 206.0003 C10H5O2NCl -0.2 H2O
196.0159 C9H7O2NCl -0.5 CO
178.0053 C9H5ONCl -0.5 H2O, CO
15 265.0350 C12H6D2O3N2Cl D2O
237.0400 C11H6D2O2N2Cl 2.2 D2O, CO
227.0302 C10H4D3O3NCl 2.0 C2H2DNO
225.0174 C10H6DO3NCl 1.1 D2O, CO,
DCN,
addition of ½
O2
207.0068 C10H4DO2NCl 0.8 D2O, H2O,
CO, DCN,
addition of ½
O2
20 225.0175 C10H6DO3NCl 1.5 DCN,
addition of ½
O2
207.0068 C10H4DO2NCl 0.8 DCN, H2O,
addition of ½
O2
20 207.0067 C10H4DO2NCl 0.7 H2O
12 225.0174 C10H6DO3NCl 1.0 addition of
H2O
179.0118 C9H4DONCl 0.4 CO
151.0167 C8H4DNCl -0.3 CO (2x)esult
ror
m)
.7
.3
.1
.2
.2
.4
.3
.1
.4
.5
.2
.0
.8process. No shifts due to either 18O- or D2O-uptake
157J Am Soc Mass Spectrom 2008, 19, 151–158 MS OF SUBSTITUTED ISOQUINOLINESwere observed for the regenerated ion at m/z 224 (data
not shown). The efficiency of restoration was surpris-
ingly high, which allowed to conduct “ping-pong”
MS/MS experiments between m/z 224 and m/z 206. The
product ion at m/z 224 was dissociated to m/z 206 at a
normalized collision energy of 25 (arbitrary units), and
the subsequent isolation and storage of m/z 206 (nor-
malized collision energy set to 5 arbitrary units) yielded
m/z 224 in high amounts that enabled MS7 experiments
going forth and back between the two precursor-/
product ions.
Conclusions
The mass spectrometric behavior of selected substituted
isoquinolines, which possess great potential for clinical
utility as prolylhydroxylase inhibitors, was studied, and
unusual dissociation pathways were observed using
in-time and in-space tandem mass spectrometry. The
formation of a particularly favored 3-carboxylic acid
structure was suggested based on various MS experi-
ments and analyses of synthetically derived com-
pounds comprising solid-phase structures of assumed
gas phase-derived product ions. Detailed mechanistic
studies employing for instance density functional the-
ory (DFT) calculation as well as measurements of addi-
tional structurally related substances might clarify
which factors are essential for the observed phenomena
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carbonyl)-amino]-acetic acid.and allow the identification of the major driving force.Acknowledgments
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